303 related articles for article (PubMed ID: 32433232)
1. Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus.
Bae S; Durand CM; Garonzik-Wang JM; Chow EKH; Kucirka LM; McAdams-DeMarco MA; Massie AB; Al Ammary F; Coresh J; Segev DL
Transplantation; 2020 Jun; 104(6):1294-1303. PubMed ID: 32433232
[TBL] [Abstract][Full Text] [Related]
2. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis.
de Paula MI; Bae S; Shaffer AA; Garonzik-Wang J; Felipe CR; Cristelli MP; Waldram MM; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
Transplantation; 2020 Oct; 104(10):2139-2147. PubMed ID: 31978003
[TBL] [Abstract][Full Text] [Related]
4. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
[TBL] [Abstract][Full Text] [Related]
5. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.
Horton PJ; Tchervenkov J; Barkun JS; Rochon C; Chaudhury PK; Znajda TL; Martinie JB; Metrakos P
J Gastrointest Surg; 2005; 9(7):896-902. PubMed ID: 16137581
[TBL] [Abstract][Full Text] [Related]
6. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.
Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS
Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
[TBL] [Abstract][Full Text] [Related]
8. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
9. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
[TBL] [Abstract][Full Text] [Related]
10. Identification of Optimal Donor-Recipient Combinations Among Human Immunodeficiency Virus (HIV)-Positive Kidney Transplant Recipients.
Locke JE; Shelton BA; Reed RD; MacLennan PA; Mehta S; Sawinski D; Segev DL
Am J Transplant; 2016 Aug; 16(8):2377-83. PubMed ID: 27140837
[TBL] [Abstract][Full Text] [Related]
11. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
Sureshkumar KK; Thai NL; Marcus RJ
Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
13. Delayed Graft Function in Simultaneous Liver Kidney Transplantation.
Weeks SR; Luo X; Haugen CE; Ottmann SE; Gurakar AO; Naqvi FF; Alqahtani SA; Philosophe B; Cameron AM; Desai NM; Segev DL; Garonzik Wang JM
Transplantation; 2020 Mar; 104(3):542-550. PubMed ID: 31403551
[TBL] [Abstract][Full Text] [Related]
14. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk.
Masset C; Boucquemont J; Garandeau C; Buron F; Morelon E; Girerd S; Ladrière M; Mourad G; Garrigue V; Cassuto E; Albano L; Foucher Y; Dantal J;
Transplantation; 2020 Mar; 104(3):613-622. PubMed ID: 31283665
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
16. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.
Kucirka LM; Durand CM; Bae S; Avery RK; Locke JE; Orandi BJ; McAdams-DeMarco M; Grams ME; Segev DL
Am J Transplant; 2016 Aug; 16(8):2368-76. PubMed ID: 27111897
[TBL] [Abstract][Full Text] [Related]
17. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis.
Lentine KL; Cheungpasitporn W; Xiao H; McAdams-DeMarco M; Lam NN; Segev DL; Bae S; Ahn JB; Hess GP; Caliskan Y; Randall HB; Kasiske BL; Schnitzler MA; Axelrod DA
Transplantation; 2021 Aug; 105(8):1840-1849. PubMed ID: 33214534
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients.
Marfo K; Akalin E; Wang C; Lu A
Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of induction antibody therapies in the nonbroadly sensitized adult deceased donor kidney transplant recipients: a retrospective cohort registry analysis.
Santos AH; Li Y; Alquadan K; Ibrahim H; Leghrouz MA; Akanit U; Womer KL; Wen X
Transpl Int; 2020 Aug; 33(8):865-877. PubMed ID: 31989680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
